Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
contrast agent
gadolinium-based contrast agent |
| gptkbp:approvalYear |
1989
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
V08CA02
|
| gptkbp:CASNumber |
92943-93-6
|
| gptkbp:containsElement |
gptkb:gadolinium
|
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:discoveredBy |
Guerbet
|
| gptkbp:eliminationHalfLife |
1.4 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C23H42GdN3O16
|
| https://www.w3.org/2000/01/rdf-schema#label |
gadoterate meglumine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
Dotarem
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
headache allergic reaction |
| gptkbp:usedFor |
magnetic resonance imaging
|
| gptkbp:bfsParent |
gptkb:gadolinium-based_contrast_agents
|
| gptkbp:bfsLayer |
7
|